Coherus Oncology, Inc. (CHRS)

NASDAQ: CHRS · Real-Time Price · USD

1.630

-0.060 (-3.55%)

At close: Mar 13, 2026, 4:00 PM EDT

1.650

+0.020 (1.23%)

After-hours: Mar 13, 2026, 7:32 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Developing and Commercializing Biosimilar Products	42.17M	26.39M	257.24M	211.04M	326.55M
Developing and Commercializing Biosimilar Products Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Total	42.17M	26.39M	257.24M	211.04M	326.55M
Total Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States of America	42.17M	26.39M	257.24M	211.04M	326.55M
United States of America Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Total	42.17M	26.39M	257.24M	211.04M	326.55M
Total Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%

Source: S&P Global Market Intelligence.